New Nasal Vaccine Approach Offers Hope Against Drug-Resistant Tuberculosis
Photo: CDC / Unsplash
Researchers at Johns Hopkins Medicine are pioneering an innovative nasal vaccine designed to combat tuberculosis, which remains the world's deadliest infectious disease. By combining two TB genes, the vaccine aims to train the immune system to eliminate bacteria that have developed resistance to standard antibiotics, offering a potential breakthrough for millions at risk.
Researchers at Johns Hopkins Medicine are pioneering an innovative nasal vaccine designed to combat tuberculosis, which remains the world’s deadliest infectious disease. By combining two TB genes, the vaccine aims to train the immune system to eliminate bacteria that have developed resistance to standard antibiotics, offering a potential breakthrough for millions at risk.